Similar articles

• Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  Seufferlein T, Bachet JB, Van Cutsem E, Rougier P; ESMO Guidelines Working Group. Seufferlein T, et al. Ann Oncol. 2012 Oct;23 Suppl 7:vii33-40. doi: 10.1093/annonc/mds224. Ann Oncol. 2012. PMID: 22997452 No abstract available.
• Palliative chemotherapy for pancreatic malignancies.

  Mehta SP. Mehta SP. Surg Clin North Am. 2010 Apr;90(2):365-75. doi: 10.1016/j.suc.2009.12.005. Surg Clin North Am. 2010. PMID: 20362792 Review.
• Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.

  Kurreck A, Weckwerth J, Modest DP, Striefler JK, Bahra M, Bischoff S, Pelzer U, Oettle H, Kruger S, Riess H, Sinn M. Kurreck A, et al. Eur J Cancer. 2021 Jun;150:250-259. doi: 10.1016/j.ejca.2021.03.036. Epub 2021 Apr 30. Eur J Cancer. 2021. PMID: 33940349
• Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.

  Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, Moik F, Barth DA, Rossmann CH, Stotz M, Schaberl-Moser R, Pichler M, Stöger H, Greil R, Djanani A, Schlick K, Gerger A. Riedl JM, et al. Eur J Cancer. 2021 Jul;151:3-13. doi: 10.1016/j.ejca.2021.03.040. Epub 2021 May 2. Eur J Cancer. 2021. PMID: 33951545
• Emerging drugs in pancreatic cancer.

  Ducreux M, Boige V, Malka D. Ducreux M, et al. Expert Opin Emerg Drugs. 2004 May;9(1):73-89. doi: 10.1517/eoed.9.1.73.32946. Expert Opin Emerg Drugs. 2004. PMID: 15155137 Review.